LumiraDx
LumiraDx Receives Notice From Nasdaq Over Missed Listing Requirement
The UK-based point-of-care diagnostics company received the letter because its common shares on the Nasdaq closed below $1 for 30 consecutive trading days.
Earnings Roundup: OraSure Technologies, Standard BioTools, LumiraDx, More
OraSure, Standard BioTools, LumiraDx, and Epigenomics reported their financial results this week.
In Brief This Week: Applied DNA Sciences, LumiraDx, Lucid Diagnostics, Nanomix, Strata Oncology
News items for the week of Aug. 15, 2022.
In Brief This Week: LumiraDx, Natera, Caris Life Sciences
News items for the week of July 18, 2022
LumiraDx to Publicly Offer 40M Shares
The net proceeds will be used for general corporate purposes, including working capital for research and development.
May 12, 2022
LumiraDx Q1 Revenues up 18 Percent
Apr 6, 2022
Oct 27, 2021
BTIG Initiates Coverage of LumiraDx With Buy Rating
Apr 7, 2021